Recent News Releases

For investor-related news, see our ASX releases here.

Aug 6, 2026

A further update on TAVNEOS® (avacopan) in the European Union

Dear ANCA‑associated vasculitis community, Further to our last update regarding TAVNEOS® (avacopan), we wanted to inform you that the European Commission (EC) has adopted a decision revoking...
Aug 6, 2026

European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries

ST. GALLEN, SWITZERLAND – 6 August, 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Commission (EC) has adopted the decision revoking the...
Jul 27, 2026

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress
Jul 24, 2026

Our Continued Commitment to the Hemophilia B Community: An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Supply and Patient Access
Jun 26, 2026

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, SWITZERLAND – 26 June 2026 Vifor...

Show per page

Filter by Company: